TrialBMC cardiovascular disorders2023

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF.

Qianyu Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.